Abstract

http://ssrn.com/abstract=902101
 
 

Footnotes (1)



 


 



Product Patent Protection - India's Interest


Meduri Aparna


ICFAI University

December 2005


Abstract:     
TRIPS, the intellectual property component of the Uruguay round of the GATT Treaty, developed a strong debate among developed and less developed countries. Developed countries welcomed the TRIPS agreement on the ground that their business interests incurred large losses due to imitation and use of their innovations by the less developed countries and, the introduction of IPRs would encourage the flow of foreign investments, transfer of technology and for greater research and development in the less developed countries. But the less developed countries negatived such introduction on the ground that the stronger IPRs result into drastic rise of product prices and also may cause harm to infant high tech industries. India was a strong opponent of TRIPS Agreement particularly the proposal for product patents on pharmaceutical innovations on the belief that the better-ordered world is one in which medical discoveries will be free of patents and there will be no profiteering from life and death. However, India unwillingly signed this international treaty on TRIPS and committed to introduce pharmaceutical product patents in the country.

Number of Pages in PDF File: 4

Keywords: TRIPS, Product Patents, Pharmaceutical Products

JEL Classification: K23

working papers series





Download This Paper

Date posted: May 18, 2006  

Suggested Citation

Aparna, Meduri, Product Patent Protection - India's Interest (December 2005). Available at SSRN: http://ssrn.com/abstract=902101 or http://dx.doi.org/10.2139/ssrn.902101

Contact Information

Meduri Aparna (Contact Author)
ICFAI University ( email )
Hyderabad
India
Feedback to SSRN


Paper statistics
Abstract Views: 2,778
Downloads: 427
Download Rank: 37,843
Footnotes:  1

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo5 in 0.484 seconds